These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25022578)

  • 1. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.
    Lahiri SD; Johnstone MR; Ross PL; McLaughlin RE; Olivier NB; Alm RA
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5704-13. PubMed ID: 25022578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases.
    Lahiri SD; Mangani S; Durand-Reville T; Benvenuti M; De Luca F; Sanyal G; Docquier JD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2496-505. PubMed ID: 23439634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.
    Lahiri SD; Alm RA
    Antimicrob Agents Chemother; 2016 May; 60(5):3183-6. PubMed ID: 26926646
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
    Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avibactam and inhibitor-resistant SHV β-lactamases.
    Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.
    Lahiri SD; Mangani S; Jahić H; Benvenuti M; Durand-Reville TF; De Luca F; Ehmann DE; Rossolini GM; Alm RA; Docquier JD
    ACS Chem Biol; 2015 Feb; 10(2):591-600. PubMed ID: 25406838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.
    Levasseur P; Girard AM; Claudon M; Goossens H; Black MT; Coleman K; Miossec C
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1606-8. PubMed ID: 22214778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.
    Lahiri SD; Bradford PA; Nichols WW; Alm RA
    J Antimicrob Chemother; 2016 Oct; 71(10):2848-55. PubMed ID: 27402011
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Karlowsky JA; Kazmierczak KM; de Jonge BLM; Hackel MA; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
    Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
    Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.